FDA Oks CAR-T Cell Therapy To Treat Certain Types Of Large B-cell Lymphoma

(RTTNews) - The U.S. Food and Drug Administration approved Yescarta or axicabtagene ciloleucel, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. The FDA granted approval of Yescarta to Kite Pharma Inc.

Yescarta, a chimeric antigen receptor or CAR T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma or NHL.

Diffuse large B-cell lymphoma or DLBCL is the most common type of NHL in adults. NHLs are cancers that begin in certain cells of the immune system and can be either fast-growing (aggressive) or slow-growing.